Antimetastatic potential of somatostatin analog SOM230 (pasireotide) in pancreatic cancer: Indirect pharmacological targeting of cancer-associated fibroblasts
Corinne Bousquet(Centre National de la Recherche Scientifique), Stéphane Pyronnet(Centre National de la Recherche Scientifique), Youssef Bakri(Mohammed V University), Marie‐Bernadette Delisle(Inserm), Camille Duluc(Inserm), Muriel Mathonnet(Inserm), Herbert Schmid(Novartis (Switzerland)), Siham Moatassim-Billah(Mohammed V University)
Cited by 0
Related Papers
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter
|Proceedings of the National Academy of Sciences|1999|290
Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
|The Journal of Pathology|2018|284